Altogether, our results indicate that the NRF2 silencing-mediated miR-206 regulation could suppress BCRP levels through c-MET/EGFR modulation, providing an additional underlying molecular mechanism for the tumor sensitization by NRF2 inhibition. The gene discussed is EGFR; the disease is neoplasm.